PTK2 and cancer: Specifically, as shown in Scheme 2, 6-HMDN inhibits the phosphorylation of FAK, thereby downregulating the expression of MMP-2, while FAK activation typically promotes the expression of MMP to enhance the invasiveness of cancer cells [38].